Actinium Pharmaceuticals traded at $1.15 this Thursday February 26th, increasing $0.01 or 0.88 percent since the previous trading session. Looking back, over the last four weeks, Actinium Pharmaceuticals gained 10.85 percent. Over the last 12 months, its price rose by 4.55 percent. Looking ahead, we forecast Actinium Pharmaceuticals to be priced at 1.08 by the end of this quarter and at 0.98 in one year, according to Trading Economics global macro models projections and analysts expectations.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).